Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Evaluation of antibiotic releasing porous polymethylmethacrylate space maintainers in an infected composite tissue defect model.

Spicer PP, Shah SR, Henslee AM, Watson BM, Kinard LA, Kretlow JD, Bevil K, Kattchee L, Bennett GN, Demian N, Mende K, Murray CK, Jansen JA, Wong ME, Mikos AG, Kasper FK.

Acta Biomater. 2013 Nov;9(11):8832-9. doi: 10.1016/j.actbio.2013.07.018. Epub 2013 Jul 25.

2.

Antibiotic-releasing porous polymethylmethacrylate constructs for osseous space maintenance and infection control.

Shi M, Kretlow JD, Nguyen A, Young S, Scott Baggett L, Wong ME, Kasper FK, Mikos AG.

Biomaterials. 2010 May;31(14):4146-56. doi: 10.1016/j.biomaterials.2010.01.112. Epub 2010 Feb 13.

3.

Degradable, antibiotic releasing poly(propylene fumarate)-based constructs for craniofacial space maintenance applications.

Henslee AM, Shah SR, Wong ME, Mikos AG, Kasper FK.

J Biomed Mater Res A. 2015 Apr;103(4):1485-97. doi: 10.1002/jbm.a.35288. Epub 2014 Aug 5.

PMID:
25046733
4.

Antibiotic-releasing porous polymethylmethacrylate/gelatin/antibiotic constructs for craniofacial tissue engineering.

Shi M, Kretlow JD, Spicer PP, Tabata Y, Demian N, Wong ME, Kasper FK, Mikos AG.

J Control Release. 2011 May 30;152(1):196-205. doi: 10.1016/j.jconrel.2011.01.029. Epub 2011 Feb 2.

5.

A rapid, flexible method for incorporating controlled antibiotic release into porous polymethylmethacrylate space maintainers for craniofacial reconstruction.

Mountziaris PM, Shah SR, Lam J, Bennett GN, Mikos AG.

Biomater Sci. 2016 Jan;4(1):121-9. doi: 10.1039/c5bm00175g.

6.

Evaluation of soft tissue coverage over porous polymethylmethacrylate space maintainers within nonhealing alveolar bone defects.

Kretlow JD, Shi M, Young S, Spicer PP, Demian N, Jansen JA, Wong ME, Kasper FK, Mikos AG.

Tissue Eng Part C Methods. 2010 Dec;16(6):1427-38. doi: 10.1089/ten.tec.2010.0046. Epub 2010 Jun 4.

7.

Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis.

Rodríguez-Hernández MJ, Jiménez-Mejias ME, Pichardo C, Cuberos L, García-Curiel A, Pachón J.

Clin Microbiol Infect. 2004 Jun;10(6):581-4.

8.

Surface characteristics of biomaterials used for space maintenance in a mandibular defect: a pilot animal study.

Nguyen C, Young S, Kretlow JD, Mikos AG, Wong M.

J Oral Maxillofac Surg. 2011 Jan;69(1):11-8. doi: 10.1016/j.joms.2010.02.026. Epub 2010 Nov 4.

PMID:
21055856
9.

fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

Dudhani RV, Turnidge JD, Nation RL, Li J.

J Antimicrob Chemother. 2010 Sep;65(9):1984-90. doi: 10.1093/jac/dkq226. Epub 2010 Jun 23.

10.

In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection.

Hornsey M, Wareham DW.

Antimicrob Agents Chemother. 2011 Jul;55(7):3534-7. doi: 10.1128/AAC.00230-11. Epub 2011 Apr 18.

11.

In situ formation of porous space maintainers in a composite tissue defect.

Spicer PP, Kretlow JD, Henslee AM, Shi M, Young S, Demian N, Jansen JA, Wong ME, Mikos AG, Kasper FK.

J Biomed Mater Res A. 2012 Apr;100(4):827-33. doi: 10.1002/jbm.a.34016. Epub 2012 Jan 12.

12.

Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.

Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Borraz C, Gudiol F.

J Antimicrob Chemother. 2004 Dec;54(6):1085-91. Epub 2004 Nov 16.

PMID:
15546972
13.

Use of porous space maintainers in staged mandibular reconstruction.

Henslee AM, Spicer PP, Shah SR, Tatara AM, Kasper FK, Mikos AG, Wong ME.

Oral Maxillofac Surg Clin North Am. 2014 May;26(2):143-9. doi: 10.1016/j.coms.2014.01.002. Review.

PMID:
24794263
14.

Investigation of colistin sensitivity via three different methods in Acinetobacter baumannii isolates with multiple antibiotic resistance.

Sinirtaş M, Akalin H, Gedikoğlu S.

Int J Infect Dis. 2009 Sep;13(5):e217-20. doi: 10.1016/j.ijid.2008.12.012. Epub 2009 Feb 20.

15.

Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.

Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ.

Int J Antimicrob Agents. 2009 Jan;33(1):33-9. doi: 10.1016/j.ijantimicag.2008.07.008. Epub 2008 Oct 2.

PMID:
18835761
16.

Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii.

Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Ardanuy C, Gudiol F.

Antimicrob Agents Chemother. 2002 Jun;46(6):1946-52.

17.

Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections.

Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, Onmus-Leone F, Preston L, St Clair K, Nikolich M, Viscount H, Wortmann G, Zapor M, Grillot-Courvalin C, Courvalin P, Clifford R, Waterman PE.

J Infect Dis. 2013 Oct 1;208(7):1142-51. doi: 10.1093/infdis/jit293. Epub 2013 Jun 28.

PMID:
23812239
19.

Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii.

López-Rojas R, Domínguez-Herrera J, McConnell MJ, Docobo-Peréz F, Smani Y, Fernández-Reyes M, Rivas L, Pachón J.

J Infect Dis. 2011 Feb 15;203(4):545-8. doi: 10.1093/infdis/jiq086. Epub 2011 Jan 7.

20.

Supplemental Content

Support Center